Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with its Zevaskyn cell therapy, including patient cancellations and manufacturing problems, though net revenue for Zevaskyn grew 31% quarter-over-quarter. Abeona has treated 12 patients since launch and expanded to seven Qualified Treatment Centers, maintaining its yearly expansion goal. The company holds $146.8 million in cash and may see growth from partnerships with Ultragenyx and Taysha through potential milestone and royalty payments.
